And ABT-199 combined with doxorubicin (DOX) or dinaciclib could effectively improve the therapeutic outcome of SCLC.85 Another Bcl-2 inhibitor, AT-101, was used to explore its antitumor activity and the mechanism of targeting cancer stem cells (CSCs) and anti-apoptotic proteins in gastro-esophageal cancers (GEC).86 AT-101 could induce apoptosis of cells with Bcl-2/Mcl-1 high expression in gastric cancer tissues and then inhibit cell proliferation and growth. This evidence concerns the gene BCL2 and small cell lung carcinoma.